Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)

CD52 and CD20 antigens are important therapeutic targets for the monoclonal antibodies (mAbs) alemtuzumab and rituximab respectively. Circulating CD52 (cCD52) and CD20 (cCD20) have prognostic utility in lymphoid malignancies. The efficacy of mAb therapy in patients with chronic lymphocytic leukaemia...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Alatrash, Gheath, Albitar, Maher, O'Brien, Susan, Wang, Xuemei, Manshouri, Taghi, Faderl, Stefan, Ferrajoli, Alessandra, Burger, Jan, Garcia-Manero, Guillermo, Kantarjian, Hagop M., Lerner, Susan, Keating, Michael J., Wierda, William G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4476391/
https://ncbi.nlm.nih.gov/pubmed/19895616
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07965.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados